Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The American Headache Society previously published a Consensus Statement on the use of newly introduced treatments for adults with migraine. This update, which is based on the expanded evidence base and emerging expert consensus concerning postapproval usage, provides practical recommendations in the absence of a formal guideline.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>This update involved four steps: (1) review of data about the efficacy, safety, and clinical use of migraine treatments introduced since the previous Statement was published; (2) incorporation of these data into a proposed update; (3) review and commentary by the Board of Directors of the American Headache Society and patients and advocates associated with the American Migraine Foundation; (4) consideration of these collective insights and integration into an updated Consensus Statement.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Since the last Consensus Statement, no evidence has emerged to alter the established principles of either acute or preventive treatment. Newly introduced acute treatments include two small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists (ubrogepant, rimegepant); a serotonin (5-HT<sub>1F</sub>) agonist (lasmiditan); a nonsteroidal anti-inflammatory drug (celecoxib oral solution); and a neuromodulatory device (remote electrical neuromodulation). New preventive treatments include an intravenous anti-CGRP ligand monoclonal antibody (eptinezumab). Several modalities, including neuromodulation (electrical trigeminal nerve stimulation, noninvasive vagus nerve stimulation, single-pulse transcranial magnetic stimulation) and biobehavioral therapy (cognitive behavioral therapy, biofeedback, relaxation therapies, mindfulness-based therapies, acceptance and commitment therapy) may be appropriate for either acute and/or preventive treatment; a neuromodulation device may be appropriate for acute migraine treatment only (remote electrical neuromodulation). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>The integration of new treatments into clinical practice should be informed by the potential for benefit relative to established therapies, as well as by the characteristics and preferences of individual patients.</p></section>

An update on migraine

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice

Migraine Treatment: When, Why, and How to Introduce Antimigraine Therapies

Migraine update. Diagnosis and treatment

New Oral Drugs for Migraine

Cardiovascular Disease and Migraine: Are the New Treatments Safe?

Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second‐Generation Gepants, and Cardiovascular Risk

Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations

Migraine: Pathophysiology, Pharmacology, Treatment and Future Trends

Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors

Future targets for migraine treatment beyond CGRP

The pathophysiological and pharmacological basis of current drug treatment of migraine headache

Migraine Management in Medically Complex Patients: a Narrative Review

CGRP therapy in primary care for migraine: prevention and acute medication

Advances in Pharmaceutic Managements of Migraine

Migraine: Advances in the Pathogenesis and Treatment

New treatments for migraine ... and other research

Migraine Treatment: Towards New Pharmacological Targets

New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication

Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence